Introduction

Gamma knife radiosurgery is a highly accurate, non-surgical procedure employing tightly focused gamma radiation to treat brain tumors, AVMs, functional disorders, and other neurological maladies. Developed in 1968 in Sweden's Karolinska Institute, the Leksell system employs several cobalt 60 sources to irradiate a target with a high dose while sparing surrounding healthy tissue. With more than 300 units world wide it's a well established treatment in contemporary neurosurgery.

The Gamma Knife Market is expected to register a CAGR of 5.0% from 2025 to 2031

Market Growth Drivers

Increased neurological disorders: An older population and improved imaging have resulted in more diagnoses of brain tumors and AVMs, propelling demand.

Minimally invasive treatments: enables outpatient, no incision procedures with faster recovery and fewer complications than regular surgery.

Advances in technology: Advances encompass integrated high resolution MRI/PET imaging, frameless immobilization, AI based planning, and robotic guidance increasing precision, workflow efficiency, and patient comfort.

Get Sample Report: https://www.theinsightpartners.com/sample/TIPRE00005916

Growth Strategies

Tech innovation & integration: Combining imaging modalities (MRI, PET), applying AI/ML algorithms to treatment planning, and creating frameless choices and mask-based immobilization. For example, deep learning algorithms are currently applied to predict 3D dose distributions, enhancing clinical workflow efficiency.

Strategic partnerships: Partnerships such as Elekta's with Brainlab to integrate planning systems—and acquisitions enhance hardware, software, and worldwide reach.

Outpatient treatment shift: Organizations such as Mayo Clinic have constructed suites to facilitate day care procedures, in keeping with cost-containment and patient preferences for reduced length of stay.

Market growth: Aggressive growth in developing economies such as India, China, Brazil, and South Africa through regional partnerships and local manufacturing.

Future Trends

Artificial intelligence adoption: AI-enabled dose planning and decision support are anticipated to standardize and automate treatment, improve plan quality and throughput.

Increased clinical application: In addition to tumors, increasingly finds application in the treatment of epilepsy, acoustic neuromas, trigeminal neuralgia, and eye lesions.

Hybrid treatment paradigms: Combination with radiosensitizers, chemotherapy, and adaptive multi modality radiation treatments presents new clinical horizons.

Medical tourism & patient centric care: Competitive rates in APAC and Asia, along with patient satisfaction orientation and flexible finance, are fueling medical tourism.

Opportunities

Emerging markets: Nations with increasing healthcare spending and improving reimbursement systems present high-growth opportunities.

R&D expansion: Development of new indications, AI-driven planning, and combination therapies can reveal new outcomes and clinical applications.

Value based care alignment: With premium being laid on patient outcomes and cost-effectiveness, would find suitable accommodation in value-oriented healthcare models.

Key Market Segments

By Disease Indication

Brain Metastasis

Cancer

Arteriovenous Malformation

Trigeminal Neuralgia

By Anatomy

Head

Neck

Other Body Parts

Key Players with Recent Developments

Varian Medical Systems

Brand synergy: As part of Siemens since April 2021, Varian enjoys upgraded R&D capabilities and expanded global presence.

Market traction: Recent end-user conversations indicate that Varian systems are increasingly being adopted in clinical environments for easier maintenance and streamlined workflows over older platforms.

Brainlab AG

Planning software innovation:

Since 2012, Brainlab's iPlan has been combined with Elekta's GammaPlan, allowing sophisticated multimodal imaging and functional targeting in planning.

Ongoing 2025: Brainlab continues to be an essential enabler of image-guided and software-assisted planning for both Elekta and CyberKnife systems.

Elekta AB

CE mark & FDA 510(k) for Elekta Esprit:

Elekta obtained CE certification in August 2022 for the Leksell Gamma Knife Esprit providing sub millimeter (0.3 mm) precision and <60 second automated planning.

By October 2022, the Esprit also attained FDA 510(k) clearance, allowing U.S. and worldwide deployment.

Conclusion

This trend is fueled by increasing prevalence of neurological disease, ongoing innovation, outpatient models of care, and increasing access in emerging markets. Ongoing investments in AI, education, and collaborations along with affordable, patient focused care will drive the future of gamma knife radiosurgery.